Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Common Equity (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Common Equity for 4 consecutive years, with $176.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 9.88% to $176.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $176.3 million, a 9.88% decrease, with the full-year FY2024 number at $161.4 million, down 12.66% from a year prior.
  • Common Equity was $176.3 million for Q3 2025 at Century Therapeutics, down from $209.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $386.7 million in Q1 2022 to a low of $161.4 million in Q4 2024.
  • A 4-year average of $246.0 million and a median of $222.1 million in 2024 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: tumbled 38.97% in 2023, then surged 35.17% in 2025.
  • Century Therapeutics' Common Equity stood at $302.7 million in 2022, then crashed by 38.97% to $184.8 million in 2023, then decreased by 12.66% to $161.4 million in 2024, then grew by 9.29% to $176.3 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Common Equity are $176.3 million (Q3 2025), $209.9 million (Q2 2025), and $240.4 million (Q1 2025).